[{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DALVANCE FDA Approval Acute Bacterial Skin Structure Infections in Pediatric","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Peptide","graph2":"AbbVie Inc"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"WEP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA\u00ae (lefamulin)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO\u00ae (tedizolid phosphate) in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XENLETA\u00ae (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva\u2019s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"$5.0 million","newsHeadline":"Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO (tedizolid phosphate) in the U.S. Through the End of 2026","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nabriva Therapeutics Expands XENLETA (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Large molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Nabriva Therapeutics"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches First Generic Version of Pylera\u00ae (Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride) Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Endo International"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches First Generic Version of Noxafil (posaconazole) Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Endo International"},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aerogen and CanSinoBIO Agree on Landmark Development and Commercial Supply Partnership for World\u2019s First Inhaled Covid-19 Vaccine Delivery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Vaccine","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen and CanSinoBIO, First Public Booster Immunization in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Vaccine","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Aerogen"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches Authorized Generic Version of Noxafil\u00ae (posaconazole) Oral Suspension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Endo Pharm"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The 5 patients in the age group birth to less than 3 months of age were not included in the efficacy analyses since they were enrolled with expanded inclusion criteria and only received the single-dose DALVANCE regimen.
Posaconazole injection is the inhibition of cytochrome P-450, which is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromise.
Posaconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane.
Bismuth subcitrate potassium and antibacterial agents (metronidazole and tetracycline hydrochloride) capsules in combination are indicated for treating H.pylori infection and duodenal ulcer disease to eradicate H. pylori.
Convidecia Air™ (homologous inactivated covid-19 vaccine) has proven to be an innovative solution that provides safe and effective protection for people through a needle-free, painless and non-invasive delivery without any serious adverse events observed.
Lead Product(s):
Homologous Inactivated Covid-19 Vaccine
Under the terms of the agreement, Er-Kim gains exclusive rights to distribute XENLETA (lefamulin) in the following countries: Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia.
Under the initial term of the agreement, Nabriva was solely responsible for marketing, sales, and distribution of SIVEXTRO (Tedizolid Phosphate) in the United States through December 31, 2023. The amendment extends the agreement to December 31, 2026.
Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine, Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.
The restructured agreement provides for additional manufacturing collaboration and regulatory support [to be provided to Sinovant by Nabriva] that is expected to help expedite the delivery of XENLETA to patients in greater China.
Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes